THE CLINICAL, LABORATORY CHARACTERISTICS AND SOME RELATED FACTORS TO MALE HYPOGONADISM AT CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL
Main Article Content
Abstract
Background: Hypogonadism is a clinical syndrome characterized by a deficiency in testosterol. This condition significantly reduces the quality of life and can have adverse effects on many organ. It is becoming increasingly attention and treatment. The prevalence of hypogonadism is higher in male with comorbidities such as hypertension, type 2 diabetes, metabolic syndrome. Due to the increasing global population and life expectancy, the number of elderly individuals is also increasing. Research objective: To describe the clinical and paraclinical characteristics identify some factors are related to male hypogonadism at Can Tho University of Medicine and Pharmacy Hospital. Materials and methods: A cross-sectional descriptive study of 30 male patients with hypogonadism from June 2022 to June 2023 at Can Tho University of Medicine and Pharmacy Hospital. Results: The average age was 40.6 years, but the majority of the surveyed group was <40 years old, accounting for 53.3%. 86.7% of patients came for examination with symptoms of erectile dysfunction, with severe erctile dysfunction accounting for 6.7%, moderate erectile dysfunction accounting for 30%, and mild erectile dysfunction accounting for 63.3%. 76.7% experienced a decrease in morning erections, 73.3% experienced physical fatigue/decreased vitality, and 50% experienced psychological stress. The mean testosterol concentration was 4.6 nmol/L. 40% of patients overweight, 23.3% were obese, 50% had hypertension, 16.7% had type 2 diabetes, and 13.3% had dyslipidemia. There was a correlation between testosterol, FSH, LH concentrations, and the degree of erectile dysfunction and decreased libido. Conclusion: Comprehensive evaluation of factors related to male hypogonadism can help improve diagnosis and treatment.
Article Details
Keywords
Male hypogonadism, testosterone, FSH, LH
References
2. Wu FCW, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. The Journal of Clinical Endocrinology & Metabolism. 2008. 93(7):2737-2745, doi: https://doi.org/10.1210/jc.2007-1972.
3. P. Dadhich, et al. Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men. Indian J Urol. 2017. 33(3), pp. 236-240, doi: 10.4103/iju.IJU_372_16
4. A Seftel. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. International journal of impotence research. 2006. 18(3), 223-228, doi: https://doi.org/10.1038/sj.ijir.3901365
5. Thomas Mulligan et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International journal of clinical practice. 2006. 60(7), 762-769, doi: https://doi.org/10.1111/j.1742-1241.2006.00992.x.
6. Jae Il Kang, et al. Correlation between serum total testosterone and the AMS and IIEF questionnaires in patients with erectile dysfunction with testosterone deficiency syndrome. Korean journal of urology. 2011. 52(6), 416-420, doi: https://doi.org/10.4111/kju.2011.52.6.416.
7. Kelleher, S, Conway, AJ, and Handelsman, DJ. Blood testosterone threshold for androgen deficiency symptoms, The Journal of Clinical Endocrinology & Metabolism. 2004. 89(8):38133817, doi: https://doi.org/10.1210/jc.2004-0143.
8. P. Kumar, et al. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res. 2010. 1(3), pp. 297-301, doi: 10.4103/0110-5558.72420.
9. Mohit Khera et al. Adult-onset hypogonadism. Mayo Clinic Proceedings. 2016. Elsevier, pp. 908-926, doi: https://doi.org/10.1016/j.mayocp.2016.04.022.
10. Nguyễn Khoa Diệu Vân, Nguyễn Thị Thục Hiền. Nghiên cứu đặc điểm lâm sàng, nồng độ Testosterone ở bệnh nhân đái tháo đường type 2 có rối loạn cương Bệnh viện Bạch Mai. 2016. Luận văn thạc sĩ.